Target intelligence / Profile preview

Paternally expressed 13 (PEG13)

Target
PEG13
Molecular classification
Long non-coding RNA (lncRNA), Imprinted gene, Other
01

Overview

Paternally expressed 13 (PEG13) is a paternally imprinted long non-coding RNA (lncRNA) gene found in humans (chromosome 8) and mice (chromosome 15)[1][2][3]. It has a key regulatory role in the brain, including modulating neural differentiation, social and sexual behavior, and the expression of other imprinted genes and neuronal function genes[1]. PEG13 also modulates inflammation, notably by suppressing the proinflammatory cytokines HMGB1 and IL-6, and its expression is associated with a reduced inflammatory response in sepsis models, making it a potential therapeutic target for inflammatory diseases[2][4]. In humans, PEG13 is linked to Birk-Barel syndrome, a rare neurological disorder[3]. Loss or dysregulation of PEG13 leads to major behavioral changes, especially related to social interaction, sexual preference, and possibly anxiety and activity levels[1]. PEG13 acts by influencing gene networks rather than encoding a protein, and its exact molecular mechanisms remain under investigation[1][2][4].

Other names
PEG13Paternally expressed 13Peg13
02

Mechanism of action

As a non-coding RNA, PEG13 regulates gene expression, including imprinted genes and inflammation-related pathways

03

Biological functions

Regulation of neuronal differentiation and functionModulation of sexual and social behaviorRegulation of imprinted gene networksModulation of inflammatory responseOther (influence on cytokine release, regulation of synaptic and hormonal gene expression)
04

Disease associations

Neurological and neurobehavioral disorders (including Birk-Barel syndrome)Inflammation (sepsis)Potential connection to epilepsyOther
05

Safety considerations

Potential challenges due to the essential role in brain development and behavioral regulationDeletion or dysregulation leads to substantial behavioral phenotypes and possible developmental issuesNo known safety concern directly tied to inhibiting PEG13 for therapy, but off-target or developmental effects may be a risk
06

Biomarkers

Elevated PEG13 expression in blood as a biomarker for sepsis and inflammationNegative correlation with HMGB1, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) in sepsis patients

Beyond the preview

Go deeper on Paternally expressed 13 (PEG13).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Paternally expressed 13 (PEG13).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call